BUY Gland Pharma Limited — Chandan Taparia, Motilal Oswal
byChandan Taparia, Motilal OswalHorizon: NA (inferred Swing (≤2wk))9 Sept 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·10 Sept · today
5 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · adjacent horizon·7 Sept · 3d ago
Gland Pharma shares: Promoter Fosun Pharma likely to divest 5% equity worth Rs 2,279 crore via block deal
NewsEt-Markets·3 Sept · 6d ago
Gland Pharma Block Deal: Fosun Pharma to sell 5% stake at ₹2,763/share
NewsCnbc-Tv18·3 Sept · 6d ago
Fosun Pharma sells 4.5% stake in Gland Pharma for Rs 2,121 crore
NewsHbl·5 Sept · 4d ago
Gland Pharma block deal: Fosun Pharma divests 99 lakh shares worth Rs 2,800 crore
NewsEt-Markets·4 Sept · 5d ago
Block deal alert! Gland Pharma shares in focus as promoter Fosun to sell 5% stake for Rs 2,279 crore
NewsEt-Markets·4 Sept · 6d ago
Gland Pharma Promoter Likely To Sell 5% Stake Via Rs 2,279 Crore Block Deal
NewsNdtv-Profit·3 Sept · 6d ago
Gland Pharma shares fall after ₹2,100 crore block deal; Promoter likely seller
NewsCnbc-Tv18·4 Sept · 6d ago
Large trade alert! Gland Pharma shares fall 3% after 1.2 crore shares change hands in 2 block deals; promoter Fosun likely seller
NewsEt-Markets·4 Sept · 6d ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Gland Pharma
- BUY — Ashish Kyal, Waves Strategy Advisors28 Oct 2026 · ~2 weeks · target ₹3,230 · Active
- BUY — Vishnu Kant Upadhyay, Master Capital Services13 Oct 2026 · ~3 months · target ₹3,400 · Active
- BUY — Kunal Parar, Choice Broking8 Oct 2026 · Same day · target ₹3,235 · Expired
- BUY — Prakash Gaba7 Oct 2026 · ~2 weeks · target ₹3,200 · SL hit
- BUY — Nomura India Research7 Oct 2026 · ~1 year · target ₹3,750 · Active
More from Chandan Taparia, Motilal Oswal
- BUY TVS Motor Company29 Oct 2026 · ~2 weeks · target ₹4,380 · Active
- BUY Laurus Labs29 Oct 2026 · ~2 weeks · target ₹2,300 · Active
- BUY BSE28 Oct 2026 · ~2 weeks · target ₹3,650 · Active
- BUY BSE28 Oct 2026 · ~2 weeks · target ₹3,550 · Active
- BUY Sona BLW Precision Forgings28 Oct 2026 · ~2 weeks · target ₹900 · Active

